Loading…
Employees: 1,144
Size Shanghai New World (600628.SS) is a China Health Care company (Medical Distributors) with a market value of $623M, the 3331st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.42 on 6 Nov 2026.
Performance Over six months the shares fell 10.8%, against -2.9% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 1.6% over the last twelve months (peer median +6.0%); the operating margin is 6.0% (peer median 1.6%).
Valuation It trades at 2.4× enterprise value to sales against a peer median of 1.0× (4th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points below its cost of capital (5.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.09B | CN¥1.09B | CN¥1.11B | CN¥1.12B | CN¥839M |
| Revenue growth | — | -2% | -1% | +34% | — |
| Gross profit | CN¥584M | CN¥446M | CN¥443M | CN¥428M | CN¥216M |
| EBITDA | n/a | CN¥230M | CN¥248M | CN¥246M | CN¥78.2M |
| Net income | CN¥58.9M | CN¥66.7M | CN¥70.0M | CN¥31.7M | -CN¥52.0M |
| Free cash flow | CN¥68.9M | CN¥25.0M | CN¥179M | CN¥179M | CN¥13.1M |
| Capital expenditure | CN¥132M | CN¥159M | CN¥161M | CN¥145M | CN¥35.0M |
| Total debt | CN¥475M | CN¥542M | CN¥572M | CN¥598M | CN¥638M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600628.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | -0.3% | 9th highest of 21 |
| 6-month return | -10.8% | -2.9% | 6th lowest of 21 |
| Distance from 52-week high | -34.3% | -20.9% | 8th lowest of 21 |
| Revenue growth (TTM) | -1.6% | +6.0% | 5th lowest of 21 |
| Operating margin | 6.0% | 1.6% | 5th highest of 21 |
| EV / Sales | 2.4× | 1.0× | 4th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 0.3% | 2.9% | 7th least demanding of 16 |
| Growth delivered (Del g) | +1.0% | +6.0% | 3rd lowest of 16 |
| Hurdle (Req g minus delivered) | -0.7 pp | -5.2 pp | 5th most demanding of 16 |
| ROIC minus cost of capital | -0.1 pp | -1.5 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | 2.4× | 0.3% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | 0.8× | 14.4% | +7.5% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 0.1× | -7.1% | +3.8% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | 1.2× | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | 4.1× | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | 0.6× | 59.0% | -7.8% |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 0.3× | 5.0% | +8.1% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 1.2× | 21.8% | +29.9% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | 0.1× | 0.4% | +2.6% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $926M | -27% | -5% | -2% | 2.0× | 17.2% | +12.4% |
| Excelsior Medical 4104.TW | Taiwan | $409M | +1% | +6% | 8% | 1.6× | 2.9% | +5.7% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |
| Gongwin Biopharm 6617.TWO | Taiwan | $388M | +50% | +22% | -571% | 267.5× | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | 0.3× | n/a | n/a |
| Shanghai Universal Biotech 301166.SZ | China | $376M | -6% | +15% | -4% | 1.2× | n/a | n/a |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 1.3× | -1.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 0.7× | -5.9% | +1.2% |
| Rongfeng 000668.SZ | China | $327M | -5% | +61% | 14% | 5.3× | 11.4% | +30.0% |
| Medios ILM1.DE | Germany | $324M | -9% | +10% | 2% | 0.2× | -1.3% | +27.1% |